AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00769054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local Infiltration Analgesia with 1 % Ropivacaine
Study NCT00769054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Local Infiltration with NaCl
Study NCT02345733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis Diet
Description: we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT02345733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic cocktail
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Study NCT02108886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
Study NCT02108886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty capsule filled with sugar
Study NCT02108886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine and vaginal secretions sampling
Description: Urine and vaginal secretions sampling, once a week in both groups
Study NCT02108886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: urine and vaginal secretions sampling
Description: Urine and vaginal secretions sampling, once a week in both groups
Study NCT03816176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate
Description: Intravenous (IV) infusion
Study NCT03816176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate
Description: Oral capsule
Study NCT03994016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WiseGuyz
Description: The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement.
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO
Study NCT01355757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Injection of Local Anesthetic
Description: Single injection of 20 ml ropivacaine 0.5%
Study NCT04161534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KT Tape
Description: in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
Study NCT04161534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm Sling
Description: An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
Study NCT04161534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm Sling
Description: An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
Study NCT04319757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
Study NCT04319757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study NCT04319757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study NCT03356886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
Study NCT00052026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: low-dose carvedilol administered twice daily for 8 months
Study NCT00052026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered twice daily for 8 months
Study NCT00052026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: high-dose carvedilol administered twice daily for 8 months
Study NCT03875638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
Study NCT03875638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo is a capsule that is identical in appearance to the levetiracetam
Study NCT03501368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
Study NCT03501368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Participants will take trametinib by mouth at a dose of 2 mg daily
Study NCT01091103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT04174352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: estrogen modulator
Study NCT04174352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FES PET/CT
Description: Radiolabeled estrogen \[18F\]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
Study NCT01701388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso exoskeleton
Description: The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT04131231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: microparticles packaging methotrexate (MPs-MTX)
Description: 50ml, intrapleural infusion, day5,6,7,8
Study NCT04131231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human interleukin-2(rhIL-2)
Description: 50ml, intrapleural infusion, day5,8,11
Study NCT02150759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion during spinal anesthesia
Study NCT02150759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion during spinal anesthesia
Study NCT02150759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: add dexmedetomidine during position change
Study NCT02150759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: add dexmedetomidine during position change
Study NCT01609621 — intervention group
Intervention type: DEVICE
Intervention: Retrograde tibiopedal arterial access
Description: Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
Study NCT03927924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound
Description: Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
Study NCT02704234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Acupuncture
Description: Active Acupuncture two times per week for 5 weeks
Study NCT02704234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: Placebo Acupuncture two times per week for 5 weeks
Study NCT02332980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02332980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO
Study NCT02332980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study NCT02332980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01993602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercises
Description: The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise.
Study NCT02728765 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
Study NCT03878524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06490003 — intervention group
Intervention type: DRUG
Intervention: Fluoro Uracil
Description: Esophageal cancer chemotherapy（First line treatment)
Study NCT02234206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chandrakanthi Choornam (CKC)
Description: 12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940
Study NCT01709734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone
Study NCT01417819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile short message service
Description: Mobile short message service reminder for appointments of parents of cataract children
Study NCT03043118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variety Intervention
Description: Vegetable flavor variety created with multiple herb and spice blends
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study NCT03308032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
Study NCT03308032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
Study NCT00816920 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination of leg veins
Description: Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
Study NCT03641339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One vector feeding
Description: Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
Study NCT03641339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four vector feeding
Description: Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
Study NCT02527135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly HIV sensitization text messages
Description: Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV.
Study NCT01837108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
Study NCT01837108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02728765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
Study NCT04597203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755-nm picosecond alexandrite laser with topical 2% hydroquinone
Description: treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
Study NCT04597203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical 2% hydroquinone
Description: treatment one side of the face with topical 2% hydroquinone
Study NCT02257008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS
Study NCT02257008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Study NCT02257008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT02257008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Study NCT02257008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT00411528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study NCT00411528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT03187860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Biopsy
Description: Bronchial biopsies will be performed on all subjects.
Study NCT00411528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00411528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel